MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, PSTV had $8,682K increase in cash & cash equivalents over the period. -$20,842K in free cash flow.

Cash Flow Overview

Change in Cash
$8,682K
Free Cash flow
-$20,842K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from sale of common sto...
    • Proceeds from sale of common sto...
    • Proceeds from sales of short-ter...
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Purchases of short-term investme...
    • Accounts payable and accrued exp...
    • Others

Cash Flow
2025-12-31
Net loss
-22,386
Depreciation and amortization
445
Accretion of discount on short-term investments
9
Noncash financing expenses
3,061
Change in fair value of derivative instruments
2,631
Stock compensation expense
1,540
Gain on sale of assets
16
Grant receivable
-249
Other assets
763
Accounts payable and accrued expenses
-5,620
Other liabilities
159
Change in operating lease liabilities
-66
Net cash used in operating activities
-20,775
Purchases of property and equipment
67
Proceeds from sale of property and equipment
30
Purchases of short-term investments
9,353
Proceeds from redemption of short-term investments
3,768
Proceeds from sales of short-term investments
4,768
Net cash used in investing activities
-854
Proceeds from credit facility
750
Repayment of credit facility
3,292
Payment of financing costs
2,250
Proceeds from issuance of notes payable and warrants
3,738
Repayment of notes payable
3,703
Proceeds from sale of common stock, pre-funded warrants, and warrants
15,926
Proceeds from sale of common stock under lincoln park purchase agreement
22,615
Payment to investors pursuant to letter agreement
3,242
Offering costs for sale of common stock
231
Net cash provided by financing activities
30,311
Net increase (decrease) in cash and cash equivalents
8,682
Cash, cash equivalents, and restricted cash at beginning of period
76
Cash, cash equivalents, and restricted cash at end of period
8,758
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from sale ofcommon stock under...$22,615K Proceeds from sale ofcommon stock,...$15,926K Proceeds from issuance ofnotes payable and...$3,738K Proceeds from creditfacility$750K Net cash provided byfinancing activities$30,311K Canceled cashflow$12,718K Net increase(decrease) in cash and cash...$8,682K Canceled cashflow$21,629K Repayment of notes payable$3,703K Repayment of creditfacility$3,292K Payment to investorspursuant to letter...$3,242K Payment of financingcosts$2,250K Offering costs for sale ofcommon stock$231K Noncash financingexpenses$3,061K Change in fair value ofderivative instruments$2,631K Stock compensationexpense$1,540K Depreciation andamortization$445K Grant receivable-$249K Other liabilities$159K Proceeds from sales ofshort-term investments$4,768K Proceeds from redemptionof short-term...$3,768K Proceeds from sale ofproperty and equipment$30K Net cash used inoperating activities-$20,775K Net cash used ininvesting activities-$854K Canceled cashflow$8,085K Canceled cashflow$8,566K Net loss-$22,386K Purchases of short-terminvestments$9,353K Accounts payable andaccrued expenses-$5,620K Other assets$763K Change in operatinglease liabilities-$66K Gain on sale of assets$16K Accretion of discount onshort-term investments$9K Purchases of property andequipment$67K

PLUS THERAPEUTICS, INC. (PSTV)

PLUS THERAPEUTICS, INC. (PSTV)